Otamixaban Explained

Otamixaban (INN) is an experimental injectable anticoagulant direct factor Xa inhibitor[1] that was investigated for the treatment for acute coronary syndrome. In 2013, Sanofi announced that it had ended development of the drug candidate after poor performance in a Phase III clinical trial.[2] [3]

Notes and References

  1. Guertin KR, Choi YM . The discovery of the Factor Xa inhibitor otamixaban: from lead identification to clinical development . Curr. Med. Chem. . 14 . 23 . 2471–81 . 2007 . 17979700 . 10.2174/092986707782023659.
  2. Chemical & Engineering News . American Chemical Society . June 10, 2013 . 91 . 23 . 17 . AstraZeneca, Sanofi Cut Programs . Sanofi is ending development on two compounds, the anticancer compound iniparib and the anticoagulant otamixaban, both of which flunked Phase III studies..
  3. Web site: Sanofi's Investigational Iniparib, Otamixaban Fail To Meet Goals, Ends Programs. RTT news. 11 April 2014.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Otamixaban".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.